Skip to main content

TCET Pathway Could Accelerate Access to Innovating Technologies

The Centers for Medicare & Medicaid Services (CMS) proposed the Transitional Coverage for Emerging Technologies (TCET) pathway to enable quicker coverage decisions for breakthrough devices needing accelerated regulatory review. As described in JAMA Health Forum, TCET allows tailored oversight based on an innovation’s specific benefits and risks.



TCET focuses on FDA Breakthrough-designated devices for serious conditions supported by limited clinical data for market authorization. By facilitating transitional coverage, TCET aims to help make cutting-edge technologies accessible to patients while additional real-world evidence is gathered to meet CMS’ “reasonable and necessary” standard. 

For developers to optimize TCET’s streamlined approach they should be sure to:

- Pursue FDA Breakthrough designation when criteria are met. This opens the TCET pathway.  

- Engage CMS early on study designs and evidence needs. Incorporate draft guidance on endpoints and real-world data.

- Enable rapid post-market product iterations while maintaining quality.

- Develop safety monitoring and launch protocols satisfying coverage safeguards. 

- Allocate resources for robust data collection and coordination with CMS under shifted evidence requirements.

This proactive, collaborative mindset allows developers to work synergistically with regulators, accelerating patient access while still demonstrating clinical value.

TCET is designed such that it may provide key advantages for AI, machine learning and other novel developments:

- Expedited coverage following truncated registries/pragmatic studies to supplement breakthrough designation data

- Flexibility to refine algorithms and update data inputs without full regulatory restarts

- Clearer expectations and endpoints for pre-market trials to meet CMS evidence needs

- Structured opportunities for manufacturer feedback on study improvements 

- Transitional coverage with “Coverage with Evidence Development” while real-world evidence is gathered

- Streamlined reviews of new data at scheduled milestones to make updated coverage determinations

By embracing TCET’s efficiency, developers can advance high-potential technologies through the pipeline with appropriate oversight. However, challenges may remain even under TCET:

- Non-breakthrough devices still face conventional regulatory burdens

- Reluctance to cover unproven categories like digital health despite clinical promise

- Real-world implementation unknowns and long-term safety monitoring needs 

- Provider training gaps and care integration difficulties

- Ongoing patient access barriers and health disparities

While a major step forward, TCET alone cannot resolve all impediments to emerging technology adoption. Still, TCET represents the type of flexible, sensible regulation needed to balance oversight and progress. As details finalize, TCET could catalyze development of transformative innovations to improve patient outcomes.

As CMS finalizes the pathway details, I’m excited to see TCET in action opening the door to cutting-edge medical breakthroughs. The alacrity of the constantly evolving medtech landscape demands regulatory nimbleness. By embracing agility through initiatives like TCET, CMS is demonstrating an impactful commitment to progress.



Comments

Post a Comment

Popular posts from this blog

The Problem of Limited-Supply Agreements for Medicare Price Negotiation

A recent JAMA Viewpoint article discusses how limited-supply agreements between brand name and generic drug makers could impact Medicare price negotiation under the Inflation Reduction Act (IRA). These agreements allow brand manufacturers to maintain some market exclusivity by limiting the supply of generic competitors. The article suggests these deals may increase as the Centers for Medicare and Medicaid Services (CMS) implements the IRA's price negotiation provisions. From a business perspective, it's understandable why brand manufacturers might find limited-supply agreements preferable to having their drugs subject to Medicare negotiation. Maintaining even partial exclusivity is likely better for revenue than triggering government-dictated price reductions. However, policymakers and patients are increasingly concerned that these deals keep prices high despite generic availability. The use of limited supply agreements could also produce unintended consequences.  Balancing som...
Post a Comment
Read more

The Future of Liquid Biopsies: Endless Possibilities for Cancer Testing

Liquid biopsies are poised to disrupt cancer testing as we know it. These novel blood tests analyze circulating tumor DNA (ctDNA) and other molecules released by cancer cells, providing a non-invasive option for detection, diagnosis, and monitoring. The promise of liquid biopsies has generated tremendous excitement, along with over $1 billion in investments and acquisitions in recent years. But how close are we to realizing their full potential?  A recent review article sounds a note of caution amidst the hype. While liquid biopsies show ability to detect cancer, evidence that they improve patient outcomes is still lacking. Randomized trials with survival endpoints are needed to prove clinical utility. However, this provides the perfect opportunity for innovative diagnostics companies. Rather than dampening enthusiasm, these evidence gaps highlight major growth possibilities if companies can demonstrate real-world value.   We envision liquid biopsies transforming oncology...
Post a Comment
Read more

FDA Green Light Inches Genetic Screening Forward

The FDA recently granted authorization for the first multi-gene test for assessing hereditary cancer risk, marking a significant advancement in genetic screening capabilities. Developed by Invitae Corporation, the Invitae Common Hereditary Cancers Panel analyzes variants in 47 genes associated with increased cancer risk. Using next-generation sequencing on DNA from blood samples, the test looks at BRCA1 and BRCA2 variants linked to breast and ovarian cancer, as well as other cancer-related genes.  (image source: Adobe Stock Images) The FDA’s approval provides a regulatory framework giving labs a clearer roadmap for developing similar multi-gene panels. With an authorized model in place, labs can proceed more confidently in navigating FDA submissions. Specifically, the de novo classification created for Invitae’s test allows future lab-developed panels to gain regulatory clearance through the expedited 510(k) pathway by demonstrating substantial equivalence. This streamlined validat...
Post a Comment
Read more